Literature DB >> 35536356

One-year follow-up of optical coherence tomography angiography microvascular findings: macular telangiectasia type 2 versus tamoxifen retinopathy.

Yu Jeong Park1, Suhwan Lee2, Young Hee Yoon3.   

Abstract

PURPOSE: To compare microstructural and microvascular changes in eyes with macular telangiectasia type 2 (MacTel2) and in those with tamoxifen retinopathy (TR) at baseline and at the 1-year follow-up using optical coherence tomography (OCT) and OCT angiography (OCTA).
METHODS: We followed up patients diagnosed with MacTel2 or TR for at least 1 year. We included 17 patients with MacTel2 (31 eyes) and 15 with TR (25 eyes) who discontinued tamoxifen use after a TR diagnosis. We performed OCT and OCTA at baseline and after 1 year.
RESULTS: Patients with MacTel2 and TR showed intraretinal cavitation, ellipsoid zone (EZ) loss, and capillary telangiectasia in the superficial and deep plexuses. EZ disruption predominantly affected the temporal region in MacTel2 (32%) and was limited to the foveal center in TR (24%). Vascular density (VD) was significantly reduced within the deep temporal parafovea and superficial fovea in MacTel2 and TR eyes, respectively. After 1 year, the MacTel2 eyes showed enlarged EZ loss, proliferative vascular invasion, and increased VD (p = 0.021) in the temporal deep plexus compared with TR eyes.
CONCLUSIONS: After 1-year follow-up, the MacTel2 eyes showed proliferative vascular remodeling, particularly in the temporal parafovea of the deep plexus with EZ loss progression, whereas the TR eyes maintained their baseline capillary rarefaction.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Macular telangiectasia type 2; Microvascular changes; Optical coherence tomography angiography; Tamoxifen retinopathy

Mesh:

Substances:

Year:  2022        PMID: 35536356     DOI: 10.1007/s00417-022-05695-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  29 in total

1.  Quantitative OCT analysis of idiopathic perifoveal telangiectasia.

Authors:  Daniel Barthelmes; Mark C Gillies; Florian K P Sutter
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05       Impact factor: 4.799

2.  Retinal vascular layers in macular telangiectasia type 2 imaged by optical coherence tomographic angiography.

Authors:  Richard F Spaide; James M Klancnik; Michael J Cooney
Journal:  JAMA Ophthalmol       Date:  2015-01       Impact factor: 7.389

3.  Prevalence and Risk Factors of Tamoxifen Retinopathy.

Authors:  Hyun-Ah Kim; Suhwan Lee; Kyu Sang Eah; Young Hee Yoon
Journal:  Ophthalmology       Date:  2019-11-07       Impact factor: 12.079

4.  Multimodal imaging in type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Irene Leung; Traci E Clemons; Tunde Peto; Alan C Bird; Daniel Pauleikhoff
Journal:  Retina       Date:  2015-04       Impact factor: 4.256

5.  Optical coherence tomography findings in tamoxifen retinopathy.

Authors:  Vincent Gualino; Salomon Y Cohen; Marie-Noëlle Delyfer; José-Alain Sahel; Alain Gaudric
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

6.  Pseudocystic foveal cavitation in tamoxifen retinopathy.

Authors:  Rishi R Doshi; Jorge A Fortun; Brian T Kim; Sander R Dubovy; Philip J Rosenfeld
Journal:  Am J Ophthalmol       Date:  2014-02-26       Impact factor: 5.258

Review 7.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

8.  Screening for ocular toxicity in asymptomatic patients treated with tamoxifen.

Authors:  J S Heier; R A Dragoo; R W Enzenauer; W J Waterhouse
Journal:  Am J Ophthalmol       Date:  1994-06-15       Impact factor: 5.258

9.  OCT Angiography and Ellipsoid Zone Mapping of Macular Telangiectasia Type 2 From the AVATAR Study.

Authors:  Anne P Runkle; Peter K Kaiser; Sunil K Srivastava; Andrew P Schachat; Jamie L Reese; Justis P Ehlers
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-07-01       Impact factor: 4.799

10.  Improvements in visual acuity and macular morphology following cessation of anti-estrogen drugs in a patient with anti-estrogen maculopathy resembling macular telangiectasia type 2: a pathogenic hypothesis.

Authors:  Akihiro Shinkai; Wataru Saito; Yuki Hashimoto; Susumu Ishida
Journal:  BMC Ophthalmol       Date:  2019-12-30       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.